Title: Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing
advanced adenomatous polyps in Black patients
Version: 2 Date: 28 Jun 2021
Reviewer:  Nagahide Matsubara
Reviewer's report:
The manuscript entitled “Short-term aspirin and statin chemoprophylaxis did not reduce the risk
of developing advanced adenomatous polyps in Black patients” by B.D. Renelus and others is
well prepared concerning the chemo-preventive effect of aspirin and statin on Black patients.
They conclude that short-term aspirin-statin did not reduce the risk of advanced adenomatous
polyps development in a cohort of Black patients. It is OK, but observation period is too short
to draw a conclusion.
People who took part in the early cardiovascular aspirin trials had fewer colorectal cancers 10
years later (Flossman et al. Lancet 2007). Meta-analysis of 8 vascular trials using aspirin revealed
fewer cancer deaths among those randomized to aspirin (Rothwell et al. Lancet 2011). When
you look at the prospective randomized trial data of aspirin on Lynch syndrome patients, it took
more than 10 years of follow up to reduce the incidence of colorectal cancer occurrence (HR
0.58) (Burn J etal. CaPP consortium Lancet 2011). More than that, this effect was only observed
with administration of high dose aspirin (600mg). According to the Women’s Health Study,
long term follow up reveals significant reduction in colorectal cancers after 10 years (Cook NR
et al. Annals of Internal medicine 2013;159:77-85).
Accordingly, this study is a little premature to draw a conclusion for aspirin to reduce the risk
of developing precursor lesion of colorectal cancer or even colorectal cancer. Observation of
additional 5 or more years may draw a definite different conclusion.
Title: Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing
advanced adenomatous polyps in Black patients
Version: 2 Date: 28 Jun 2021
Reviewer:  Nagahide Matsubara
Reviewer's report:
The manuscript entitled “Short-term aspirin and statin chemoprophylaxis did not reduce the risk
of developing advanced adenomatous polyps in Black patients” by B.D. Renelus and others is
well prepared concerning the chemo-preventive effect of aspirin and statin on Black patients.
They conclude that short-term aspirin-statin did not reduce the risk of advanced adenomatous
polyps development in a cohort of Black patients. It is OK, but observation period is too short
to draw a conclusion.
People who took part in the early cardiovascular aspirin trials had fewer colorectal cancers 10
years later (Flossman et al. Lancet 2007). Meta-analysis of 8 vascular trials using aspirin revealed
fewer cancer deaths among those randomized to aspirin (Rothwell et al. Lancet 2011). When
you look at the prospective randomized trial data of aspirin on Lynch syndrome patients, it took
more than 10 years of follow up to reduce the incidence of colorectal cancer occurrence (HR
0.58) (Burn J etal. CaPP consortium Lancet 2011). More than that, this effect was only observed
with administration of high dose aspirin (600mg). According to the Women’s Health Study,
long term follow up reveals significant reduction in colorectal cancers after 10 years (Cook NR
et al. Annals of Internal medicine 2013;159:77-85).
Accordingly, this study is a little premature to draw a conclusion for aspirin to reduce the risk
of developing precursor lesion of colorectal cancer or even colorectal cancer. Observation of
additional 5 or more years may draw a definite different conclusion.
Please review this paper.
user
Title: Short-term aspirin and statin chemoprophylaxis did not reduce the risk of developing
advanced adenomatous polyps in Black patients
Version: 2 Date: 28 Jun 2021
Reviewer:  Nagahide Matsubara
Reviewer's report:
The manuscript entitled “Short-term aspirin and statin chemoprophylaxis did not reduce the risk
of developing advanced adenomatous polyps in Black patients” by B.D. Renelus and others is
well prepared concerning the chemo-preventive effect of aspirin and statin on Black patients.
They conclude that short-term aspirin-statin did not reduce the risk of advanced adenomatous
polyps development in a cohort of Black patients. It is OK, but observation period is too short
to draw a conclusion.
People who took part in the early cardiovascular aspirin trials had fewer colorectal cancers 10
years later (Flossman et al. Lancet 2007). Meta-analysis of 8 vascular trials using aspirin revealed
fewer cancer deaths among those randomized to aspirin (Rothwell et al. Lancet 2011). When
you look at the prospective randomized trial data of aspirin on Lynch syndrome patients, it took
more than 10 years of follow up to reduce the incidence of colorectal cancer occurrence (HR
0.58) (Burn J etal. CaPP consortium Lancet 2011). More than that, this effect was only observed
with administration of high dose aspirin (600mg). According to the Women’s Health Study,
long term follow up reveals significant reduction in colorectal cancers after 10 years (Cook NR
et al. Annals of Internal medicine 2013;159:77-85).
Accordingly, this study is a little premature to draw a conclusion for aspirin to reduce the risk
of developing precursor lesion of colorectal cancer or even colorectal cancer. Observation of
additional 5 or more years may draw a definite different conclusion.
assistant